[Featured Stock] Jinwon Life Sciences Rises on News of Participation in Rare Disease Gene Therapy Development

[Asia Economy Reporter Jang Hyowon] VGXI, a subsidiary of Jinwon Life Sciences, is showing strong performance following news of its participation as a partner in the development of gene therapies for rare diseases.

As of 10:25 AM on the 11th, Jinwon Life Sciences is trading at 43,500 KRW, up 3.69% from the previous day.

On this day, Jinwon Life Sciences announced that its DNA vaccine and gene therapy specialized contract development and manufacturing organization (CDMO) subsidiary VGXI will participate as a partner in a rare disease gene therapy development project supported by the non-profit organization 'Rare Trait Hope Fund.'

VGXI plans to produce and supply plasmid raw materials for clinical-grade pharmaceuticals for the gene therapy of the rare disease aspartylglucosaminuria (AGU).

This content was produced with the assistance of AI translation services.